Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adjustable Brodalumab Dosage Regimen Compared With Standard Brodalumab Treatment for 52 Weeks in Subjects With Moderate-to-severe Plaque Psoriasis and ≥120 kg Body Weight

NCT04306315 is registered in ClinicalTrials.gov with LEO Pharma as lead sponsor.

NCT NCT04306315
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04306315 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adjustable Brodalumab Dosage Regimen Compared With Standard Brodalumab Treatment for 52 Weeks in Subjects With Moderate-to-severe Plaque Psoriasis and ≥120 kg Body Weight
Lead sponsor
LEO Pharma
Phase
Phase 4
Overall status
Completed
Start date
July 21, 2022
Completion date
January 5, 2026
Enrollment
385 (actual)
Sites
81

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis vulgaris